PredictImmune attracts Series B
UK-based PredictImmune, a developer of prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, has closed its Series B funding round at 10 million pounds. The investors included Parkwalk, Cambridge Enterprise and BGF.
30 July 2019•1 min read
